{"organizations": [], "uuid": "7aba4194ef3cdc66e86f8e2f303e997ead9649ce", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/7", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/04/30/globe-newswire-t2-biosystems-announces-2018-first-quarter-financial-and-operational-results-release-and-conference-call-date.html", "country": "US", "domain_rank": 767, "title": "T2 Biosystems Announces 2018 First Quarter Financial and Operational Results Release and Conference Call Date", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.998, "site_type": "news", "published": "2018-04-30T16:00:00.000+03:00", "replies_count": 0, "uuid": "7aba4194ef3cdc66e86f8e2f303e997ead9649ce"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/04/30/globe-newswire-t2-biosystems-announces-2018-first-quarter-financial-and-operational-results-release-and-conference-call-date.html", "ord_in_thread": 0, "title": "T2 Biosystems Announces 2018 First Quarter Financial and Operational Results Release and Conference Call Date", "locations": [], "entities": {"persons": [], "locations": [{"name": "mass.", "sentiment": "none"}, {"name": "lexington", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "LEXINGTON, Mass., April 30, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, today announced that it will release its 2018 first quarter financial and operational results after the market closes on Tuesday, May 8, 2018. In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Eastern Time on Tuesday, May 8, 2018 to discuss the financial results and other business developments.\nInterested parties may access the live call via telephone by dialing 1-877-300-8521 (U.S.) or 1-412-317-6026 (International). To listen to the live call via T2 Biosystems' website, go to www.t2biosystems.com , in the Investors/Events & Presentations section. A webcast replay of the call will be available following the conclusion of the call, also in the Investors/Events & Presentations section of the website.\nAbout T2 Biosystems\nT2 Biosystems, an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, improves patient care and reduces the cost of healthcare by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, and the T2Bacteria® Panel and are powered by the proprietary T2 Magnetic Resonance technology, or T2MR®. T2Bacteria Panel is commercially available in Europe and other countries that accept the CE Mark and is available for research use only in the U.S. For more information, please visit www.t2biosystems.com .\nMedia Contact:\nTom Langford, Feinstein Kean Healthcare\ntom.langford@fkhealth.com\n617-761-6775\nInvestor Contact:\nMatthew Clawson, W2O Group\nmclawson@w2ogroup.com\n949-370-8500\nSource:T2 Biosystems, Inc.", "external_links": ["https://www.globenewswire.com/Tracker?data=Pf9HRaGoeJkcDl5v2-4wXo6GeQavHB3vLjSKK75RB_mRWziLsNBAMU5ebAFCO68NsE6tWWxm27i8INz6MrtII_53NVuD6KEOlunwabSld3FZkU_RNKUkC-NUGMA_Du_RGWw_QdQDRwNbtRPPC7FoQ1ipB58gve94t35jo-e3ofJE6AuU0OfbJx3xgA8Rr6V35hsRdDdenFutbvGQZyeIDJCk4ok941R5sSM5vt0y1ZEp4IB-aGFd0qb61ziaE6s6sAF2TSavvjsOMNii8FcaAw==", "https://www.globenewswire.com/Tracker?data=oYYH0PUU4rLMTNoVYSeArX783LEmxFxx-3_Dwf78nypc-dOyqDEi7iDKwMiLosbOob-hGVg_UsRZRZ9WQOhk5oAx8GCGqYcdGuMw2Zkgu5U=", "https://www.globenewswire.com/Tracker?data=Pf9HRaGoeJkcDl5v2-4wXk1RkumbHmyG4MaY1pu_mNKsGIKXCI0W18_U6Lb5Lk0N3vsBfAxMYm1yBVgzehVoxwNYo8OyD237E83IvSV_6cTcbryEPHkEAIR61XenLQsq0kwUcRG9HF6Rq7OKHuiVEgtMJA9aRW_HDG5krrTKbWZyjp_4R8x7mg0uo8RDEzBCQViz-OAHFjsbeqqya9Oxeo5h7PDMG5QjuK-SKqgByQPrAdf5WvBc9ys5z4bW_B8rzQ2CcJ4uwhVqDbrVh5i43KNCMjUyX-mjCmlwfv2MEqrlVljhEkY76n5widxWMphuueDVSqcnuIwrVVwmj6ztT8gjsJQfytMZxpkkjyw7LeFyeNxoN2mKppKJGn10aeUFdw5xXTBcAhzRspzGDIf0zZAZ3050xshZ39Uot1ZTPJqlV5V-_ijRXS6PbRLsIky73ZQzw65SyMIqIA2R5jRAEwFsBEGaXmNVCBVUj8K", "https://www.globenewswire.com/NewsRoom/AttachmentNg/21ce43b1-81a5-42af-8c47-c2df2e179d21", "https://www.globenewswire.com/Tracker?data=BC7pSheU7YvolYLjWBRA-czKpZXVYsAWMH1ZtceYHo_JJuLz2PkjJLUqTTSUr-MTJnL4uxRbkgarOergNeorTPTSfJdsvf-yIz2Pfslr01I="], "published": "2018-04-30T16:00:00.000+03:00", "crawled": "2018-04-30T18:14:14.005+03:00", "highlightTitle": ""}